HRP20201732T1 - A22k, desb27, b29r, dez b30, na položaju epsilon u lizinu 22 aciliranog analoga ljudskog inzulina - Google Patents
A22k, desb27, b29r, dez b30, na položaju epsilon u lizinu 22 aciliranog analoga ljudskog inzulina Download PDFInfo
- Publication number
- HRP20201732T1 HRP20201732T1 HRP20201732TT HRP20201732T HRP20201732T1 HR P20201732 T1 HRP20201732 T1 HR P20201732T1 HR P20201732T T HRP20201732T T HR P20201732TT HR P20201732 T HRP20201732 T HR P20201732T HR P20201732 T1 HRP20201732 T1 HR P20201732T1
- Authority
- HR
- Croatia
- Prior art keywords
- dezb30
- dezb27
- eps
- human insulin
- gglu
- Prior art date
Links
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title claims 52
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 title claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
- 239000004472 Lysine Substances 0.000 title 1
- 101150019032 B29R gene Proteins 0.000 claims 56
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 50
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 28
- 239000004026 insulin derivative Substances 0.000 claims 26
- 125000002252 acyl group Chemical group 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 239000011701 zinc Substances 0.000 claims 5
- 229910052725 zinc Inorganic materials 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 claims 4
- 150000007513 acids Chemical class 0.000 claims 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- BTZVDPWKGXMQFW-UHFFFAOYSA-N Pentadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCC(O)=O BTZVDPWKGXMQFW-UHFFFAOYSA-N 0.000 claims 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 2
- -1 Zn2+ ions Chemical class 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- QQHJDPROMQRDLA-UHFFFAOYSA-N hexadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 claims 2
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical group OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000011661 metabolic syndrome X Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Natural products OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14157215 | 2014-02-28 | ||
| EP15707102.8A EP3110840B1 (de) | 2014-02-28 | 2015-02-26 | A22k, desb27, b29r, des b30 an der epsilon-position von lysin-22-acyliertem menschlichem insulin-analogon |
| PCT/EP2015/053989 WO2015128403A2 (en) | 2014-02-28 | 2015-02-26 | Novel insulin derivatives and the medical uses hereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201732T1 true HRP20201732T1 (hr) | 2020-12-25 |
Family
ID=50184804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201732TT HRP20201732T1 (hr) | 2014-02-28 | 2020-10-27 | A22k, desb27, b29r, dez b30, na položaju epsilon u lizinu 22 aciliranog analoga ljudskog inzulina |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10040839B2 (de) |
| EP (1) | EP3110840B1 (de) |
| JP (1) | JP6580583B2 (de) |
| KR (1) | KR20160125988A (de) |
| CN (1) | CN106459171B (de) |
| AR (1) | AR099569A1 (de) |
| AU (1) | AU2015222135B2 (de) |
| BR (1) | BR112016017193A2 (de) |
| CA (1) | CA2941103A1 (de) |
| DK (1) | DK3110840T3 (de) |
| ES (1) | ES2831848T3 (de) |
| HR (1) | HRP20201732T1 (de) |
| HU (1) | HUE051355T2 (de) |
| IL (1) | IL246757B (de) |
| MX (1) | MX368387B (de) |
| PL (1) | PL3110840T3 (de) |
| PT (1) | PT3110840T (de) |
| RS (1) | RS61137B1 (de) |
| RU (1) | RU2684456C2 (de) |
| SA (1) | SA516371705B1 (de) |
| SI (1) | SI3110840T1 (de) |
| TW (1) | TWI686403B (de) |
| WO (1) | WO2015128403A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170028031A1 (en) * | 2014-03-07 | 2017-02-02 | Klavs Holger Jørgensen | Novel fast acting insulin preparations |
| JP2018531900A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー／エス | 新規インスリン誘導体及びその医学的使用 |
| AR110193A1 (es) * | 2016-11-21 | 2019-03-06 | Univ Case Western Reserve | Análogos de insulina de acción rápida de estabilidad mejorada |
| KR101909052B1 (ko) * | 2017-02-09 | 2018-10-17 | 강원대학교산학협력단 | 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물 |
| MA49339A (fr) * | 2017-04-05 | 2020-02-12 | Novo Nordisk As | Conjugués insuline-fc à extension oligomère |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| CN111032685A (zh) * | 2017-08-17 | 2020-04-17 | 诺沃挪第克公司 | 新型酰化胰岛素类似物及其用途 |
| MX2020004251A (es) * | 2017-10-19 | 2021-05-27 | Mona E Buice | Composición tópica para cicatrización mejorada de heridas abiertas. |
| TWI829687B (zh) * | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| BR112021011050A2 (pt) | 2018-12-11 | 2021-08-31 | Sanofi | Ligante peptídico |
| US20220125941A1 (en) * | 2019-02-13 | 2022-04-28 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof |
| US20220306695A1 (en) * | 2019-08-27 | 2022-09-29 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| CA3159114A1 (en) | 2019-12-11 | 2021-06-17 | Frantisek Hubalek | Novel insulin analogues and uses thereof |
| KR20240013778A (ko) * | 2021-05-24 | 2024-01-30 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 신규한 아실화된 인슐린 유사체 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3869437A (en) | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
| GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
| US3864325A (en) | 1971-11-18 | 1975-02-04 | Nat Res Dev | (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| KR910700262A (ko) * | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
| AU641721B2 (en) * | 1989-12-21 | 1993-09-30 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| HU217684B (hu) | 1993-09-17 | 2000-03-28 | Novo Nordisk A/S | Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6703017B1 (en) * | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| JP3872105B2 (ja) | 1995-03-17 | 2007-01-24 | ノボ ノルディスク アクティーゼルスカブ | インスリン誘導体 |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| US5898067A (en) | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| ATE321783T1 (de) | 1997-03-20 | 2006-04-15 | Novo Nordisk As | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. |
| CA2306905A1 (en) | 1997-10-24 | 1999-05-06 | Eli Lilly And Company | Fatty acid-acylated insulin analogs |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| DE69815877T2 (de) | 1997-10-24 | 2004-05-19 | Novo Nordisk A/S | Aggregate von menschlichen insulinderivaten |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
| CA2334859A1 (en) | 1998-06-12 | 1999-12-23 | Kings College London | Insulin analogue |
| WO2001000675A1 (en) | 1999-06-29 | 2001-01-04 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
| WO2001093837A2 (en) | 2000-06-08 | 2001-12-13 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| JP2005526009A (ja) | 2001-12-02 | 2005-09-02 | ノボ ノルディスク アクティーゼルスカブ | 新規グルコース依存性インスリン |
| AU2002346490A1 (en) | 2001-12-20 | 2003-07-09 | Eli Lilly And Company | Insulin molecule having protracted time action |
| AU2003208316A1 (en) | 2002-03-13 | 2003-09-22 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| US20040138099A1 (en) | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| BRPI0409600A (pt) | 2003-04-29 | 2006-04-18 | Lilly Co Eli | análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina |
| WO2005005477A2 (en) | 2003-07-11 | 2005-01-20 | Novo Nordisk A/S | Stabilised insulin compositions |
| US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
| PL2107069T3 (pl) | 2003-08-05 | 2013-06-28 | Novo Nordisk As | Nowe pochodne insuliny |
| KR101152470B1 (ko) | 2003-08-13 | 2012-06-01 | 바이오콘 리미티드 | 치료제용 마이크로-입자 지방산 염 고형 투약 제형 |
| JP2007532096A (ja) | 2003-11-14 | 2007-11-15 | ノボ ノルディスク アクティーゼルスカブ | アシル化されたインスリンの製造方法 |
| CN102816228A (zh) | 2003-12-03 | 2012-12-12 | 诺和诺德公司 | 单链胰岛素 |
| WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
| AU2005269753B2 (en) | 2004-07-19 | 2011-08-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
| JP4933455B2 (ja) | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー／エス | 新規のインスリン誘導体 |
| ES2490243T3 (es) | 2005-02-02 | 2014-09-03 | Novo Nordisk A/S | Derivados de insulina |
| EP1863840A1 (de) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Pegyliertes, einkettiges insulin |
| ES2371361T3 (es) | 2005-12-28 | 2011-12-30 | Novo Nordisk A/S | Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones. |
| US8722620B2 (en) | 2006-02-27 | 2014-05-13 | Novo Nordisk A/S | Insulin derivatives |
| RU2451029C2 (ru) | 2006-05-09 | 2012-05-20 | Ново Нордиск А/С | Производное инсулина |
| US8796205B2 (en) | 2006-05-09 | 2014-08-05 | Novo Nordisk A/S | Insulin derivative |
| JP2009544716A (ja) | 2006-07-27 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | 肺送達のためのインスリン含有エアロゾル化可能製剤 |
| EP2049149B1 (de) | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Pegylierte verlängerte insuline |
| HUE029512T2 (en) * | 2006-09-22 | 2017-03-28 | Novo Nordisk As | Protease Resistant Insulin Analogs |
| WO2008145721A2 (en) | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009015456A1 (en) | 2007-07-30 | 2009-02-05 | Generex Pharmaceuticals Inc. | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray |
| EP2178912B1 (de) * | 2007-08-15 | 2015-07-08 | Novo Nordisk A/S | Insulinanaloge mit acyl- und alkylenglycolteilen |
| CN101932601B (zh) | 2007-11-08 | 2016-08-03 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| PL2209800T3 (pl) | 2007-11-16 | 2013-12-31 | Novo Nordisk As | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| WO2009112583A2 (en) * | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| US8637647B2 (en) | 2008-09-12 | 2014-01-28 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| MX2011004357A (es) | 2008-10-30 | 2011-05-23 | Novo Nordisk As | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario. |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| EP2448962B1 (de) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin-derivate |
| RU2556340C2 (ru) * | 2009-07-31 | 2015-07-10 | Санофи-Авентис Дойчланд Гмбх | Композиция инсулина длительного действия |
| CA2795091A1 (en) | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| EP2585484A1 (de) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Zusätzliche disulfidbindungen enthaltende insulinanaloga |
| WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| WO2012010553A1 (en) | 2010-07-20 | 2012-01-26 | Novo Nordisk A/S | N-terminal modified fgf21 compounds |
| EP2720711A1 (de) | 2011-06-15 | 2014-04-23 | Novo Nordisk A/S | Mehrfach substituierte insuline |
| BR112014010139A2 (pt) | 2011-10-27 | 2017-04-25 | Univ Case Western Reserve | formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo |
-
2015
- 2015-02-25 AR ARP150100559A patent/AR099569A1/es unknown
- 2015-02-26 CN CN201580010746.3A patent/CN106459171B/zh active Active
- 2015-02-26 RS RS20201399A patent/RS61137B1/sr unknown
- 2015-02-26 PL PL15707102T patent/PL3110840T3/pl unknown
- 2015-02-26 SI SI201531416T patent/SI3110840T1/sl unknown
- 2015-02-26 JP JP2016554498A patent/JP6580583B2/ja active Active
- 2015-02-26 WO PCT/EP2015/053989 patent/WO2015128403A2/en active Application Filing
- 2015-02-26 CA CA2941103A patent/CA2941103A1/en not_active Withdrawn
- 2015-02-26 US US15/121,206 patent/US10040839B2/en active Active
- 2015-02-26 KR KR1020167024826A patent/KR20160125988A/ko not_active Application Discontinuation
- 2015-02-26 PT PT157071028T patent/PT3110840T/pt unknown
- 2015-02-26 TW TW104106145A patent/TWI686403B/zh not_active IP Right Cessation
- 2015-02-26 RU RU2016135543A patent/RU2684456C2/ru active
- 2015-02-26 ES ES15707102T patent/ES2831848T3/es active Active
- 2015-02-26 MX MX2016010899A patent/MX368387B/es active IP Right Grant
- 2015-02-26 BR BR112016017193A patent/BR112016017193A2/pt not_active Application Discontinuation
- 2015-02-26 DK DK15707102.8T patent/DK3110840T3/da active
- 2015-02-26 AU AU2015222135A patent/AU2015222135B2/en not_active Ceased
- 2015-02-26 HU HUE15707102A patent/HUE051355T2/hu unknown
- 2015-02-26 EP EP15707102.8A patent/EP3110840B1/de active Active
-
2016
- 2016-07-13 IL IL246757A patent/IL246757B/en active IP Right Grant
- 2016-08-21 SA SA516371705A patent/SA516371705B1/ar unknown
-
2020
- 2020-10-27 HR HRP20201732TT patent/HRP20201732T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016135543A3 (de) | 2018-08-30 |
| EP3110840A2 (de) | 2017-01-04 |
| JP6580583B2 (ja) | 2019-09-25 |
| JP2017508741A (ja) | 2017-03-30 |
| ES2831848T3 (es) | 2021-06-09 |
| HUE051355T2 (hu) | 2021-03-01 |
| CN106459171A (zh) | 2017-02-22 |
| PL3110840T3 (pl) | 2021-04-06 |
| KR20160125988A (ko) | 2016-11-01 |
| AU2015222135B2 (en) | 2018-12-20 |
| IL246757B (en) | 2020-04-30 |
| US20170008945A1 (en) | 2017-01-12 |
| SI3110840T1 (sl) | 2020-12-31 |
| BR112016017193A2 (pt) | 2017-10-03 |
| CN106459171B (zh) | 2020-12-15 |
| RU2684456C2 (ru) | 2019-04-09 |
| SA516371705B1 (ar) | 2019-10-08 |
| MX2016010899A (es) | 2016-11-18 |
| WO2015128403A2 (en) | 2015-09-03 |
| AR099569A1 (es) | 2016-08-03 |
| DK3110840T3 (da) | 2020-11-02 |
| RS61137B1 (sr) | 2020-12-31 |
| PT3110840T (pt) | 2020-11-26 |
| MX368387B (es) | 2019-10-01 |
| IL246757A0 (en) | 2016-08-31 |
| US10040839B2 (en) | 2018-08-07 |
| AU2015222135A1 (en) | 2016-07-28 |
| RU2016135543A (ru) | 2018-03-30 |
| EP3110840B1 (de) | 2020-10-21 |
| WO2015128403A3 (en) | 2015-12-10 |
| TWI686403B (zh) | 2020-03-01 |
| CA2941103A1 (en) | 2015-09-03 |
| TW201620930A (zh) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201732T1 (hr) | A22k, desb27, b29r, dez b30, na položaju epsilon u lizinu 22 aciliranog analoga ljudskog inzulina | |
| JP2017508741A5 (de) | ||
| JP2013533227A5 (de) | ||
| CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
| MY189770A (en) | Biaryl derivative as gpr120 agonists | |
| RU2013131913A (ru) | Твердые композиции, содержащие агонист glp и соль n-(2-гидроксибензоил)амино)каприловой кислоты | |
| CO6410287A2 (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma | |
| BR112012012947B8 (pt) | sal de hemitartarato e composição farmacêutica compreendendo o mesmo | |
| PT2280965E (pt) | Ésteres e tioésteres de ácido tiazol-4-carboxílico como agentes para a protecção de plantas | |
| ATE557030T1 (de) | Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung | |
| UA109774C2 (uk) | Кристалічні форми саксагліптину та процес його одержання (варіанти) | |
| MA32175B1 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
| WO2010136121A3 (de) | Zusammensetzung enthaltend sorbitanmonocaprylat und antimikrobielle wirkstoffe | |
| CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
| RU2012100397A (ru) | Препарат, содержащий инсулин, никотинамид и аминокислоту | |
| JP2012526123A5 (de) | ||
| BRPI0416444B8 (pt) | composto de ácido borônico heterocíclico, composição farmacêutica, e, combinação farmacêutica compreendendo o mesmo | |
| WO2008050101A3 (en) | Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk | |
| JP2018505146A5 (de) | ||
| NO20061614L (no) | Benzimidazolacetonitriler | |
| HRP20211281T1 (hr) | Pripravci koji sadrže inzulin | |
| JP2015519322A5 (de) | ||
| JP2015513544A5 (de) | ||
| NZ594244A (en) | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof | |
| NO20061599L (no) | Benzoksazol acetonitriler |